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We read with interest the recent paper by Arinaminpathy et al estimating the potential impact 
of adherence technologies on tuberculosis (TB) in India.1 We wish to highlight an important 
aspect of TB burden that these technologies have the potential to address which has not been 
widely acknowledged or investigated. Patient-centered TB care can only be achieved by 
reducing the economic burden that “free” care puts on individuals and their households. The 
third pillar of the End TB strategy, of 0% of people with TB facing catastrophic costs,2 is often 
overlooked relative to TB incidence and mortality. Patient-incurred costs are considered 
catastrophic if total costs are 20% or more of annual household income due to TB disease. By 
the end of 2019, 49% (varying at country level from 19-83%) of people with TB were still faced 
with these costs.2 TB affects the poorest most, who are least able to absorb these costs, and 
it is therefore important to monitor the distribution of TB care-associated costs and outcomes 
by socio-economic status.3 To reach the goal of reducing catastrophic costs and to address 
the true burden of TB, we need to ensure that TB care is more affordable by reducing direct 
and indirect patient-incurred costs.  
 
Digital adherence technologies (DATs), that monitor and remind patients to take medication, 
are a promising tool to reducing these costs by enabling individualised patient care, potentially 
reducing health facility visits required under Directly Observed Therapy Short course (DOTs) 
and accompanying income loss. Given that TB treatment success is already high, 
approximately 85% globally,2 and failure is a result of a variety of underlying factors, 
epidemiological impact may be limited. However, the often-overlooked economic impact of 
these tools through providing patient-centered care likely overshadows their direct 
epidemiological benefit. In Table 1, we compare for five high TB burden countries treatment 
outcomes, number of health facility visits and catastrophic costs incurred. This highlights the 
high proportion of TB patients experiencing catastrophic costs and the burden of repeated 
health facility visits, as opposed to already low treatment failure rates. While there is limited 
variation in treatment success (and even less scope for DATs to solve the underlying problem), 
the number of visits do vary, and could contribute to reducing patient costs. 
 
The economic burden of TB care is driven by income loss as well as the cost (due to travel 
and time off work) of collecting medication at the facility.3 DATs could lead to a schedule of 
fewer treatment visits, which may empower patients to continue productive activities. In 
addition, if DATs lead to better patient support and treatment adherence, previous evidence 
suggests that this may increase wellbeing and treatment success, and therefore reduce 
income losses from being too ill to work.4 
 
Unfortunately, the current evidence of both the epidemiological or patient-cost impact of DATs 
is limited, and likely to be highly setting-specific due to differences in number of health facility 
visits and treatment success in the standard of care, as illustrated in Table 1.5 There is also 
no existing evidence on the distributional effect of DATs by socioeconomic status yet. If only 
the rich benefit from DATs, due to differences in the distribution of phone ownership between 
socio-economic status groups, the utility of DATs in improving treatment outcomes and 
reducing patient costs among those most affected by TB are undermined.6 It is therefore vital 
that we understand the impact of DATs across different socioeconomic status groups, thus 
improving their ability to improve equity by reducing barriers to their use and effectiveness 
among some groups.  
 
It is key that these questions are addressed in pragmatic studies, as achieving the potential of 
digital tools will be dependent on how they are adapted to routine care, and how their use 
shapes the behaviour of patients and providers. Previous pragmatic TB studies have 
demonstrated that guidelines and reality may differ strongly when it comes to the patient 
experience;7 if patients where already attending the health facility less than is currently 
reported or if clinicians don’t act on the information from DATs, then we may see a lower than 
expected impact of DATs in reducing patient costs. If trials require access to a mobile phone, 
usually required for complete engagement with DATs, they will exclude the vital experiences 
of those patients without such access, usually those with less resources, where TB patients 
and those at risk of catastrophic costs are likely overrepresented6. Rather than ignore the 
problem, we need studies that explore provision of phone access in the intervention where 
necessary.  
 
The importance of evidence on digital technology to support TB care has become increasingly 
clear during the COVID-19 pandemic, as  tools to support patients while their movements are 
restricted.2 While it may be tempting to simply implement DATs widely, the lack of pragmatic 
evidence means that the effectiveness, acceptability and cost implications of the variety of 
tools available is unknown.  
 
As we look to fill these gaps, our focus should be to achieve maximum benefit for a patient’s 
livelihood, as well as their health.  
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Table 1: Epidemiological and economic context in five high TB burden countries. Data for 2019 
publicly available from the World Health Organization, except where indicated otherwise.8 In 
comparison, delivery of treatment support with the use of DATs could require as few as six 
health facility visits for monthly collection of medicines.  





rate in new & 
relapse cases in 
the public sector 
Typical number of 
health facility visits 






Ethiopia 112 597 88% 76 40%9 
Philippines 419 102 83% 62 35% 
South Africa 222 350 71% 6 47%10 
Tanzania 82 166 92% 18 45% 
Ukraine 28 539 77% 195 - 
 
